3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis
Main Article Content
Keywords
atopic dermatitis, tralokinumab
References
1. Weidinger S, Novak N. Lancet . 2016;387(10023):1109 1122.
2. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36(9):1409 1431.
3. de Bruin Weller M, et al. Acta Derm Venereol 2021;101:adv00402.
4. Blauvelt A, et al. Poster presented at: American Academy of Dermatology Annual Meeting; March 25 29, 2022, Boston, MA.
5. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190 9622(22)02345 3.
6. Simpson E, et al. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) Conference; December 13 14, 2020,Virtual.
7. Chuang Stein C. Pharm Stat 2011; 10:3 7.
2. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36(9):1409 1431.
3. de Bruin Weller M, et al. Acta Derm Venereol 2021;101:adv00402.
4. Blauvelt A, et al. Poster presented at: American Academy of Dermatology Annual Meeting; March 25 29, 2022, Boston, MA.
5. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190 9622(22)02345 3.
6. Simpson E, et al. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) Conference; December 13 14, 2020,Virtual.
7. Chuang Stein C. Pharm Stat 2011; 10:3 7.